| n | Total direct costs in € | Median | SD | p value§ | Total indirect costs in € | Median | SD | p value§ | Nursing care level costs in € | Median | SD | p value§ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Â | Â | Â | Â | 0.207 | Â | Â | Â | 0.839 | Â | Â | Â | 0.809 |
 Male | 95 | 5213 | 2655 | 5927 |  | 3291 | 1371 | 4063 |  | 1149 | 948 | 1002 |  |
 Female | 89 | 4667 | 1873 | 6259 |  | 3071 | 548 | 4612 |  | 1178 | 1635 | 1032 |  |
Age | Â | Â | Â | Â | 0.632* | Â | Â | Â | 0.099* | Â | Â | Â | 0.005* |
 0 to 3 years | 24 | 4554 | 2786 | 5358 |  | 4396 | 3231 | 4771 |  | 589 | 474 | 645 |  |
 4 to 10 years | 78 | 5047 | 2519 | 5970 |  | 2923 | 269 | 4635 |  | 1127 | 948 | 1027 |  |
 11 to < 22 years | 73 | 5088 | 1556 | 6578 |  | 2796 | 645 | 3687 |  | 1358 | 1635 | 1042 |  |
Number of antiseizure drugs |  |  |  |  |  < 0.001# |  |  |  | 0.002 |  |  |  |  < 0.001 |
 ≥ 2 | 94 | 6829 | 3205 | 7147 |  | 4172 | 2553 | 4814 |  | 1458 | 1635 | 956 |  |
 0–1 | 90 | 2985 | 1256 | 3871 |  | 2153 | 215 | 3488 |  | 855 | 0 | 985 |  |
mTOR inhibitors intake |  |  |  |  |  < 0.001# |  |  |  | 0.087 |  |  |  | 0.097 |
 Yes | 49 | 11,459 | 11,358 | 5945 |  | 2322 | 430 | 3795 |  | 1367 | 1635 | 1023 |  |
 No | 135 | 2586 | 1346 | 4085 |  | 3497 | 1371 | 4476 |  | 1089 | 948 | 1004 |  |
Seizures |  |  |  |  |  < 0.001 |  |  |  | 0.006 |  |  |  | 0.002 |
 Recurrent seizures | 88 | 6852 | 3765 | 6821 |  | 4014 | 2258 | 4768 |  | 1408 | 1635 | 992 |  |
 Seizure free > 1 year or no seizures | 96 | 3204 | 1196 | 4707 |  | 2423 | 215 | 3744 |  | 938 | 948 | 984 |  |
Epilepsy |  |  |  |  | 0.002 |  |  |  | 0.043 |  |  |  |  < 0.001 |
 Yes (91.8%) | 169 | 5230 | 2384 | 6213 |  | 3351 | 860 | 4390 |  | 1251 | 1635 | 1003 |  |
 No (8.2%) | 15 | 1778 | 711 | 2839 |  | 1308 | 0 | 3051 |  | 172 | 0 | 473 |  |
Structural brain disorders | Â | Â | Â | Â | 0.022 | Â | Â | Â | 0.059 | Â | Â | Â | 0.170 |
 Yes (83.2%) | 153 | 5321 | 2388 | 6293 |  | 3369 | 860 | 4424 |  | 1211 | 1635 | 993 |  |
 No (16.8%) | 31 | 3111 | 1211 | 4541 |  | 2273 | 0 | 3742 |  | 925 | 0 | 1096 |  |
Psychiatric disorders |  |  |  |  |  < 0.001 |  |  |  |  < 0.001# |  |  |  |  < 0.001# |
 Yes (51.1%) | 94 | 6372 | 2802 | 6564 |  | 4387 | 2848 | 4883 |  | 1727 | 2184 | 890 |  |
 No (48.9%) | 90 | 3463 | 1213 | 5157 |  | 1929 | 161 | 3233 |  | 574 | 0 | 774 |  |
Heart and circulatory manifestations | Â | Â | Â | Â | 0.008 | Â | Â | Â | 0.133 | Â | Â | Â | 0.059 |
 Yes (66.8%) | 123 | 5755 | 2655 | 6678 |  | 3550 | 1097 | 4394 |  | 1257 | 1635 | 1044 |  |
 No (33.2%) | 61 | 3324 | 1611 | 4245 |  | 2447 | 430 | 4125 |  | 973 | 948 | 930 |  |
Kidney and urinary tract manifestations | Â | Â | Â | Â | 0.392 | Â | Â | Â | 0.113 | Â | Â | Â | 0.010 |
 Yes (53.3%) | 98 | 4714 | 1993 | 6227 |  | 3552 | 1075 | 4380 |  | 1341 | 1635 | 1028 |  |
 No (46.7%) | 86 | 5217 | 2389 | 5931 |  | 2765 | 269 | 4252 |  | 960 | 948 | 964 |  |
Skin manifestations | Â | Â | Â | Â | 0.150 | Â | Â | Â | 0.659 | Â | Â | Â | 0.110 |
 Yes (85.9%) | 158 | 4676 | 1890 | 6106 |  | 3139 | 645 | 4206 |  | 1212 | 1635 | 1018 |  |
 No (14.1%) | 26 | 6606 | 4946 | 5749 |  | 3457 | 323 | 5082 |  | 865 | 474 | 950 |  |
Other disorders | Â | Â | Â | Â | 0.600 | Â | Â | Â | 0.899 | Â | Â | Â | 0.991 |
 Yes (29.9%) | 55 | 4134 | 2000 | 4685 |  | 2868 | 548 | 3808 |  | 1166 | 948 | 982 |  |
 No (70.1%) | 129 | 5296 | 2122 | 6570 |  | 3319 | 645 | 4537 |  | 1162 | 1635 | 1031 |  |
Level of disability |  |  |  |  |  < 0.001 |  |  |  |  < 0.001# |  |  |  |  < 0.001# |
 None or ≤ 60% | 61 | 3515 | 1057 | 5560 |  | 1544 | 0 | 3235 |  | 187 | 0 | 529 |  |
 70–100% | 123 | 5660 | 2495 | 6221 |  | 3998 | 2742 | 4574 |  | 1647 | 1635 | 831 |  |
Total Disorders |  |  |  |  | 0.009* |  |  |  | 0.016* |  |  |  |  < 0.001* |
 1–2 Manifestations (8.7%) | 16 | 1282 | 894 | 1365 |  | 1593 | 0 | 3805 |  | 323 | 0 | 604 |  |
 3 Manifestations (13%) | 24 | 3705 | 1522 | 4194 |  | 1637 | 0 | 2811 |  | 403 | 0 | 736 |  |
 4 Manifestations (17.9%) | 33 | 5916 | 2085 | 6097 |  | 3475 | 1468 | 5171 |  | 1139 | 948 | 900 |  |
 5 Manifestations (32.6%) | 60 | 5839 | 2432 | 7021 |  | 3087 | 860 | 4037 |  | 1367 | 1635 | 972 |  |
 6–7 Manifestations (27.8%) | 51 | 5011 | 2403 | 6168 |  | 4337 | 2957 | 4561 |  | 1560 | 1635 | 1027 |  |